Private Wealth Asset Management LLC increased its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 285.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,114 shares of the company’s stock after purchasing an additional 63,059 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.7% of Private Wealth Asset Management LLC’s investment portfolio, making the stock its 28th largest holding. Private Wealth Asset Management LLC’s holdings in Merck & Co., Inc. were worth $12,489,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of MRK. Alteri Wealth LLC boosted its holdings in Merck & Co., Inc. by 4.1% during the third quarter. Alteri Wealth LLC now owns 5,946 shares of the company’s stock worth $864,000 after buying an additional 234 shares in the last quarter. Private Advisor Group LLC grew its position in Merck & Co., Inc. by 39.6% during the third quarter. Private Advisor Group LLC now owns 372,092 shares of the company’s stock valued at $54,069,000 after buying an additional 105,526 shares during the period. Tyche Wealth Partners LLC increased its holdings in Merck & Co., Inc. by 44.0% in the third quarter. Tyche Wealth Partners LLC now owns 12,360 shares of the company’s stock valued at $1,796,000 after buying an additional 3,777 shares in the last quarter. Hartford Funds Management Co LLC raised its holdings in Merck & Co., Inc. by 45.0% in the 3rd quarter. Hartford Funds Management Co LLC now owns 11,920 shares of the company’s stock worth $1,732,000 after purchasing an additional 3,697 shares during the period. Finally, Ieq Capital LLC grew its holdings in Merck & Co., Inc. by 0.5% in the third quarter. Ieq Capital LLC now owns 803,040 shares of the company’s stock valued at $116,690,000 after purchasing an additional 3,826 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the sale, the executive vice president owned 112,955 shares of the company’s stock, valued at $16,718,469.55. The trade was a 34.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.17% of the company’s stock.
Merck & Co., Inc. Price Performance
Merck & Co., Inc. stock opened at $132.74 on Friday. The company has a fifty day simple moving average of $145.49 and a 200-day simple moving average of $129.20. The firm has a market capitalization of $327.24 billion, a price-to-earnings ratio of 136.85, a PEG ratio of 6.32 and a beta of 0.13. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11. Merck & Co., Inc. has a 52-week low of $93.90 and a 52-week high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same period in the previous year, the business posted $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, December 15th. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio is 350.52%.
Merck & Co., Inc. News Summary
These are some of the MRK news items that stood out recently:
- Positive Sentiment: A German court overturned a preliminary injunction that had barred Merck from offering its subcutaneous Keytruda formulation in Germany. This removes an immediate obstacle to distribution, though Halozyme says it will pursue a separate patent-infringement lawsuit seeking permanent relief. Article: Halozyme slips as German court overturns injunction against Merck
- Positive Sentiment: Merck increased its quarterly dividend 3.5% to $0.88 per share, supporting its income appeal. Article: Merck dividend announcement
- Negative Sentiment: Merck halted development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the candidate’s benefit-risk profile did not justify continuing. The move removes a late-stage blood-cancer program from its pipeline. Article: Merck Ends Nemtabrutinib Development
Analyst Upgrades and Downgrades
A number of research firms have recently commented on MRK. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research report on Wednesday, August 12th. Wells Fargo & Company increased their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. Citigroup lifted their price target on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research note on Monday, October 12th. The Goldman Sachs Group raised their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Finally, Guggenheim lifted their price objective on Merck & Co., Inc. from $170.00 to $171.00 and gave the stock a “buy” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have given a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.
View Our Latest Analysis on MRK
Merck & Co., Inc. Company Profile
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
